Breaking News

Samsung Bioepis, Catalent in Biosimilar Supply Pact

Catalent to provide fill-finish production services for biosimilar to Enbrel

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Catalent Pharma Solutions has partnered with Korea-based Samsung Bioepis Co. to provide fill-finish production services for the commercial supply of SB4, a biosimilar referencing Enbrel (etanercept), which is used in the treatment of rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis and plaque psoriasis. Catalent will provide the services from its 265,000 sq.-ft. sterile pre-filled syringe facility in Brussels, Belgium.   SB4 is the first etanercept biosimilar to receive regul...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters